<DOC>
	<DOCNO>NCT00260364</DOCNO>
	<brief_summary>Pancreatic cancer aggressive , largely chemo-resistant disease poor prognosis . EGFR VEGF overexpressed pancreatic cancer think contribute tumour development progression . The combination gemcitabine capecitabine recently show effective advanced pancreatic cancer . The combination gemcitabine plus erlotinib also show effective advanced pancreatic cancer . The aim study ass whether combine chemotherapy doublet ( gemcitabine plus capecitabine ) biologic doublet ( erlotinib plus bevacizumab ) safe effective way treat advance pancreatic cancer target multiple tumour stimulate mechanism simultaneously .</brief_summary>
	<brief_title>Combining Erlotinib Plus Bevacizumab Gemcitabine Plus Capecitabine Treat Advanced Pancreatic Cancer</brief_title>
	<detailed_description>To establish safety efficacy combination four drug ( capecitabine , gemcitabine , erlotinib bevacizumab ) treatment patient locally advance metastatic pancreatic cancer . The study divide two part : Part A ( Phase I ) : Is establish optimal dose capecitabine combination gemcitabine , bevacizumab erlotinib . This part study necessary order characterise increase side effect may occur result combination drug . The dose capecitabine increase cohort contain 3 6 patient ( accord standard dose escalation study design ) whilst side effect closely monitor . The dos three drug remain fixed period : - Gemcitabine : 1000 mg/m2 Days 1 , 8 , 15 - Bevacizumab : 5 mg/kg every two week iv - Erlotinib : 100 mg/day orally Maximum tolerate dose dose 2 cohort three six patient experience dose-limiting toxicity within first cycle ( 28 day ) treatment . The recommend dose evaluation one dose level . Part B ( Phase II ) : Once recommend dose capecitabine chosen , use remainder trial characterise efficacy safety drug combination group patient .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas Locally advance metastatic disease Not amenable curative resection No invasion adjacent organ ( e.g. , duodenum stomach ) CT scan Unidimensionally measurable disease assess CT accordance Response Evaluation Criteria Solid Tumors ( RECIST ) guideline . No evidence brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Eastern Cooperative Oncology Group ( ECOG ) 02 Life expectancy : Greater 3 month Hematopoietic : Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic : Bilirubin ≤ upper limit normal Serum albumin &gt; 26 g/litre Renal : Creatinine ≤ 180 micromoles/litre OR Creatinine clearance ≥ 50 mL/min Cardiovascular : No clinically significant cardiovascular disease No uncontrolled hypertension ( i.e. , blood pressure &gt; 150/90 mm Hg medication ) No arterial thromboembolic event within past 6 month , include follow : Myocardial infarction Unstable angina pectoris Cerebrovascular accident Transient ischemic attack No New York Heart Association grade IIIV congestive heart failure No serious cardiac arrhythmia require medication OTHER : Not pregnant breast feed Fertile patient must use effective contraception study participation No serious nonhealing wound , ulcer , bone fracture No infection require parenteral antibiotic No major bleed diathesis coagulopathy No significant traumatic injury within past 28 day No surgery within last 28 day anticipation need major surgery course study treatment No active malignancy except nonmelanoma skin cancer cervical cancer insitu No history know dihydropyrimidine dehydrogenase ( DPD ) deficiency No lack physical integrity upper gastrointestinal tract , malabsorption syndrome , inability take oral medication PRIOR CONCURRENT THERAPY : No previous chemotherapy , radiotherapy investigational drug treatment metastatic disease ( include VEGF EGFR antagonist ) No previous preoperative adjuvant chemotherapy , radiotherapy investigational drug treatment . No full dose anticoagulation ( i.e . warfarin full dose low molecular weight heparin ) prior start study treatment . No ongoing treatment aspirin ( &gt; 325 mg/day ) medication know predispose gastrointestinal ulceration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Recurrent carcinoma pancreas</keyword>
	<keyword>Adenocarcinoma pancreas</keyword>
	<keyword>Stage II carcinoma pancreas</keyword>
	<keyword>Stage III carcinoma pancreas</keyword>
	<keyword>Stage IVA carcinoma pancreas</keyword>
	<keyword>Stage IVB carcinoma pancreas</keyword>
</DOC>